Trial Profile
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Prednisone; Vincristine
- Indications Acute biphenotypic leukaemia; Burkitt's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 04 Apr 2022 Number of treatment arms have been increased from 1 to 6 by the addition of 5 more experimental arms for different dose levels.
- 06 Jul 2020 Status changed from recruiting to active, no longer recruiting.